Crohn’s disease

October 14, 2019October 14, 2019

Prometheus and Takeda Collaborate on Development of Targeted IBD Therapies

News

Biopharmaceutical company Prometheus Biosciences is collaborating with pharmaceutical firm Takeda to discover, develop, and commercialize a new generation of targeted therapies for inflammatory bowel disease (IBD). The global, multi-target strategic ... Read more

September 30, 2019September 30, 2019

Galapagos NV Launching Phase 1 Trial for Dual Action Anti-inflammatory Molecule

News

Galapagos NV‘s potential new therapy for inflammatory bowel disease (IBD) — which stimulates anti-inflammatory signals while inhibiting pro-inflammatory ones — will move into Phase 1 clinical testing, the company announced. ... Read more

September 25, 2019September 25, 2019

PD-L2 a Potential Target to Prevent Inflammation in Crohn’s Disease, Study Reveals

News

Inhibition of the signals triggered by a molecule called PD-L2 may prevent activation of autoimmunity in the gut and the progression of Crohn’s disease, a preliminary study suggests. “This study ... Read more

September 13, 2019September 13, 2019

Human Microbiome Project Reveals Causes of Disrupted Gut in IBD Patients

News

Differences in molecular events in the gut contribute to the disrupted microbiome and flare-ups in patients with inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, according to a ... Read more

September 11, 2019September 11, 2019

Crohn’s and Colitis Canada Awards $2.8M in IBD Research Projects

News

In hopes of finding new treatments and developing programs to aid Canadians with inflammatory bowel disease (IBD), Crohn’s and Colitis Canada is granting $2.8 million to 11 teams of scientists. ... Read more

September 9, 2019

Blocking FN14 Protein May Prevent Intestinal Inflammation, Help Treat Crohn’s Disease, Study Says

News

Inhibiting the inflammatory molecule Fn14 with new compounds or antibodies may reduce inflammation and tissue scarring in people with Crohn’s disease, a study suggests. The study, “TWEAK/Fn14 Is Overexpressed in ... Read more

August 23, 2019August 23, 2019

Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD

News

Landos Biopharma’s investigational BT-11 therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is continuing testing in Phase 2 clinical trials — some of which are, ... Read more

August 12, 2019August 12, 2019

IBD Patients at Higher Risk of Developing Type 2 Diabetes, Study in Denmark Suggests

News

Patients with inflammatory bowel disease (IBD) are at higher risk of developing type 2 diabetes, compared with the general population, according to a study conducted in Denmark. The study, “Inflammatory ... Read more

July 30, 2019July 30, 2019

Clinical Trial in Israel Will Evaluate Cannabidiol-based Product for Crohn’s Disease

News

The Israel-based company Stero Biotechs announced it soon will conduct a study to test a cannabidiol (CBD)-based solution as a potential treatment for steroid-dependent Crohn’s disease (SDCD). SDCD is a ... Read more

July 15, 2019July 15, 2019

Plant-based Diet Beneficial to Crohn’s Patients, Case Study Suggests

News

A high-fiber diet rich in plant proteins and whole foods may be effective to treat Crohn’s disease, according to a recently published case report. “This case study offers hope for ... Read more